Skip to main content

Cancer Metastasis

Study Provides New Insights into the Genetic Complexity of Cancer Metastasis



When cancer spreads from a primary tumor to new sites throughout the body, it undergoes changes that increase its genetic complexity.

A new study from researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) provides fresh insights about how cancers evolve when they metastasize - insights that could aid in developing strategies to improve the effectiveness of treatment.

The team - led by collaborators Dr. Luc Morris, a surgeon and cancer genetics research lab director at MSK, Dr. Xi Kathy Zhou, a professor of research in population health sciences at Weill Cornell Medicine, and Dr. Chaitanya Bandlamudi, a cancer genomics researcher at MSK - examined the genomic profiles of more than 3,700 patients across 24 cancer types who had multiple tumor sites biopsied over time.

The samples were profiled using MSK's proprietary tumor sequencing test. This allowed the research team to compare the genetic profiles of an initial tumor and metastatic site from the same patient.
Metastatic Tumors Harbor More Copy-Number Alterations

The team’s findings, which were published June 2 in Nature Genetics, showed that tumors evolve over time, and that metastases tend to accumulate more copy-number alterations (CNAs) than mutations. This led the researchers to wonder why CNAs, but not mutations, were so commonly emerging when tumors metastasized.

Mutations are like small typos in the genetic code that can affect how a gene functions, leading to the production of abnormal proteins or the alteration of gene expression. CNAs, on the other hand, are larger scale duplications or deletions of genetic material.

One extreme form of CNA - genome doubling - turned out to be important during the process of metastasis.

“We found that whole-genome duplication - which is the doubling of the entire set of chromosomes in a cancer cell - was the most common genetic event during metastasis, occurring in nearly one-third of patients," explained study first author Dr. Karena Zhao, who conducted research at MSK while attending medical school at Weill Cornell Medical College.

As cancer cells divide and make mistakes in replicating their DNA, mutations accumulate. Some mutations help the cells grow faster, while other mutations can affect essential genes and be harmful to the cell.

“Genome doubling allows cancer cells to hedge their bets, creating additional copies of genes, so that one copy can be mutated or deleted, while the other copy survives intact,” Dr. Zhou added. “This enhances the tumor cell’s ability to adapt, survive, and resist treatments.”

Understanding Genomic Differences Between Primary and Metastatic Tumors Is Critical


Unlike CNAs, more mutations can actually make tumors more visible to the immune system. That’s because the changes to their genetic sequences can make them produce abnormal proteins, which are then treated like a foreign threat by the immune system. The team found that CNAs made tumors resistant, while mutations made tumors more susceptible to immunotherapy.

“In the end, our study found that during metastasis, cancer cells tend to evolve by maximizing CNAs, while not generating too many mutations that could potentially stimulate an immune response,” Dr. Bandlamudi said.

Together, the findings suggest that newer strategies, such as therapies to target genetic instability in these highly altered cells or to alter the tumor microenvironment, could be critical for creating lasting responses in metastatic cancer, the researchers said.

“Understanding these key genomic differences between primary and metastatic tumors is vital for clinical care, as biomarkers like CNAs and tumor mutational burden are increasingly used by clinicians to inform decision-making, especially around the use of immunotherapy drugs,” Dr. Morris said.

cancer metastasis, tumor progression, metastatic cascade, epithelial-mesenchymal transition, circulating tumor cells, invasion and migration, angiogenesis, lymphatic spread, bone metastasis, brain metastasis, lung metastasis, liver metastasis, metastasis suppression, cancer microenvironment, exosomes in cancer, cancer biomarkers, cancer stem cells, metastatic niche, immunotherapy in metastasis, targeted therapy

#CancerMetastasis, #TumorProgression, #MetastaticCascade, #EMT, #CTCs, #InvasionAndMigration, #Angiogenesis, #LymphaticSpread, #BoneMetastasis, #BrainMetastasis, #LungMetastasis, #LiverMetastasis, #MetastasisSuppression, #TumorMicroenvironment, #CancerExosomes, #CancerBiomarkers, #CancerStemCells, #MetastaticNiche, #MetastasisResearch, #TargetedTherapy

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare
linkedin.com/in/genetics-research-160337363/

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more